• Completed

NCT02412878: Phase 3 - Once-weekly vs Twice-weekly Carfilzomib With Dexa in Relapsed MM (ARROW)

Updated: Jun 13

Phase 3 A.R.R.O.W. trial - ARROW

Kd

The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in adults with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent (IMiD).


Sponsor

Amgen


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT02412878


Official Title: A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing


First Posted : April 9, 2015


Click here for details on ClinicalTrials.gov

 

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

 

PMID: 29866475

Lancet Oncol;July 2018

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study


Click here for details

 

Locations

United States, Arizona

United States, Maryland

United States, New Jersey

United States, New York

United States, Pennsylvania

United States, Texas

Canada, Alberta

Canada, British Columbia

Canada, Newfoundland and Labrador

Canada, Nova Scotia

Canada, Ontario

Canada, Quebec

Canada

Australia, New South Wales

Australia, Victoria

New Zealand

Europe

United Kingdom

Belgium

Czechia

Denmark

Finland

France

Germany

Greece

Hungary

Italy

Norway

Poland

Romania

Spain

Sweden

Asia

Japan






Posts Archive